| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $10,595,733 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Stampacchia Otello | director | 1 | $8M | 0 | $0 | $8M |
| Bonita David P | director | 1 | $2.5M | 0 | $0 | $2.5M |
| SLATTERY JOSEPH P | director | 1 | $95,840 | 0 | $0 | $95,840 |
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Over the last 12 months, insiders at ImageneBio Inc have bought $10.6M and sold $0 worth of ImageneBio Inc stock.
On average, over the past 5 years, insiders at ImageneBio Inc have bought $6.54M and sold $797,472 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Stampacchia Otello (director) — $8M. Bonita David P (director) — $2.5M. SLATTERY JOSEPH P (director) — $95,840.
The last purchase of 16,000 shares for transaction amount of $95,840 was made by SLATTERY JOSEPH P (director) on 2025‑12‑24.
| 2025-12-24 | SLATTERY JOSEPH P | director | 16,000 0.1287% | $5.99 | $95,840 | +11.62% | ||
| 2025-07-25 | Stampacchia Otello | director | 267,556 10.7425% | $29.90 | $8M | -58.33% | ||
| 2025-07-25 | Bonita David P | director | 83,611 3.357% | $29.90 | $2.5M | -58.33% | ||
| 2022-06-24 | ORBIMED ADVISORS LLC | director | 162,000 1.0796% | $4.96 | $803,975 | -21.69% | ||
| 2022-06-24 | Bonita David P | director | 162,000 1.0796% | $4.96 | $803,975 | -21.69% | ||
| 2022-06-23 | ORBIMED ADVISORS LLC | director | 23,419 0.1167% | $3.71 | $86,884 | +1.45% | ||
| 2022-06-22 | Bonita David P | director | 90,225 0.4351% | $3.59 | $324,046 | +14.75% | ||
| 2022-06-22 | OrbiMed Genesis GP LLC | 66,806 0.3185% | $3.55 | $237,161 | +14.75% | |||
| 2022-06-22 | ORBIMED ADVISORS LLC | director | 66,806 0.3185% | $3.55 | $237,161 | +14.75% | ||
| 2022-01-11 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 964 0.0155% | $12.00 | $11,568 | -63.56% | |
| 2021-12-14 | Sale | FORMELA JEAN FRANCOIS | director | 5,959 0.112% | $14.00 | $83,426 | -63.59% | |
| 2021-12-14 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 5,959 0.112% | $14.00 | $83,426 | -63.59% | |
| 2021-12-13 | Sale | FORMELA JEAN FRANCOIS | director | 8,330 0.1638% | $14.64 | $121,951 | -64.74% | |
| 2021-12-13 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 8,330 0.1638% | $14.64 | $121,951 | -64.74% | |
| 2021-12-10 | Sale | FORMELA JEAN FRANCOIS | director | 11,989 0.242% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 11,989 0.242% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 1,000 0.0198% | $14.76 | $14,760 | -64.33% | |
| 2021-03-30 | ORBIMED ADVISORS LLC | director | 423,400 9.0968% | $16.00 | $6.77M | -49.34% | ||
| 2021-03-30 | Bonita David P | director | 423,400 9.0968% | $16.00 | $6.77M | -49.34% | ||
| 2021-03-30 | FORMELA JEAN FRANCOIS | director | 125,000 2.6856% | $16.00 | $2M | -49.34% |
| Stampacchia Otello | director | 454982 4.0678% | $2.57M | 1 | 0 | |
| Bonita David P | director | 287885 2.5739% | $1.63M | 4 | 0 | <0.0001% |
| SLATTERY JOSEPH P | director | 16000 0.143% | $90,400.00 | 1 | 0 | |
| ORBIMED ADVISORS LLC | director | 2098097 18.7581% | $11.85M | 4 | 0 | <0.0001% |
| OrbiMed Genesis GP LLC | 1912678 17.1004% | $10.81M | 1 | 0 | +14.75% | |
| FORMELA JEAN FRANCOIS | director | 1241935 11.1036% | $7.02M | 1 | 3 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 1241935 11.1036% | $7.02M | 1 | 3 | <0.0001% |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | 44475 0.3976% | $251,283.75 | 0 | 2 |
$5,626,766 | 114 | -34.35% | $54.9M | |
$155,630,608 | 79 | -24.53% | $62.71M | |
$1,695,621 | 55 | 17.90% | $68.76M | |
$103,288,323 | 51 | 4.78% | $62.95M | |
$4,898,715 | 46 | 40.75% | $63.77M | |
$24,478,755 | 37 | -34.59% | $63.5M | |
$6,818,859 | 36 | 47.81% | $57.1M | |
$27,151,286 | 27 | -16.85% | $60.88M | |
$1,602,584 | 20 | 15.26% | $70.39M | |
$20,234,041 | 17 | 2.09% | $73.08M | |
$17,594,514 | 16 | -20.37% | $64.26M | |
$277,862 | 15 | 59.79% | $55.01M | |
$19,300,035 | 11 | 45.88% | $54.4M | |
ImageneBio Inc (IMA) | $20,042,003 | 10 | -19.50% | $63.2M |
$45,000,000 | 6 | -31.22% | $60.29M | |
$106,599,960 | 6 | -7.63% | $75.19M | |
$401,951 | 4 | 57.41% | $75M | |
$762,555 | 4 | -34.52% | $63.31M | |
$67,369,250 | 3 | -22.09% | $52.7M |
| Increased Positions | 26 | +81.25% | 1M | +26.1% |
| Decreased Positions | 11 | -34.38% | 1M | -25.7% |
| New Positions | 14 | New | 928,718 | New |
| Sold Out Positions | 6 | Sold Out | 1M | Sold Out |
| Total Postitions | 47 | +46.88% | 5M | +0.4% |